ARS Pharmaceuticals Inc
SPRY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$277.08M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $277.08 Million |
|---|---|
| Enterprise Value | $268.92 Million |
| Earnings per Share | $-1.74 |
| Beta | 0.88 |
| Outstanding Shares | 99,312,526 |
Return
| Return on Equity | -1721.80% |
|---|---|
| Return on Assets | -86.35% |
| Return on Invested Capital | -113.57% |
Valuation & Multiples
| P/E Ratio | -1.55 |
|---|---|
| PEG | -3.99 |
| Price to Sales | 2.79 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.3 |
| Enterprise Value to EBIT | -1.26 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.30
Consensus analyst estimateRevenue Estimate
$41.99 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 8, 2027
EPS Estimate
$-0.35
Consensus analyst estimateRevenue Estimate
$30.31 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 24.39% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.58%▼ 88.23% |
|---|---|
| Total Invested | $15.31M▼ 97.90% |
| Investors Holding | 37▼ 180.00% |
About ARS Pharmaceuticals Inc
54 employees
Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administe...